Navigation Links
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Date:11/30/2009

/IV) Graft versus Host Disease. ATIR(TM) thereby significantly improves the outcome of the transplant procedure. Moreover, it enables the use of a mismatched, related (haplo-identical) donor, thus providing virtually everyone with an immediately available donor and treatment, thereby addressing a high unmet medical need as patients eligible for an allogeneic transplantation but without a matched donor available in general have no treatment options left.

ATIR(TM) has been granted orphan drug designations from both the FDA and the EMEA.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development company with cell based products in clinical development. The company develops products that offer novel treatment options for terminally ill cancer patients and address significant unmet medical needs. The key focus indication for Kiadis Pharma is limitations and complications of bone marrow transplantation procedures. Kiadis Pharma is located in Amsterdam, The Netherlands. For more information about Kiadis Pharma, please visit http://www.kiadis.com.

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.

SOURCE Kiadis Pharma


'/>"/>
SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
6. Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
7. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
8. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
11. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  The Lindsley F. Kimball Research Institute of the ... Grand Challenges Explorations winner, an initiative funded by ... Sara Lustigman , Head of the Laboratory of ... research project, titled Innovative 3-D in vitro ... to screen drugs to help eliminate onchocerciasis (river blindness) in ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Alpha ... distributor , will be exhibiting for the 13th ... of Medical Instrumentation (AAMI) 2013 Conference and Expo. ... support, distribute, and manufacture healthcare technologies. This year’s ... Long Beach, California. , The three-day event ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
Breaking Biology Technology:New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... FORTUNE,S 100 Fastest-Growing Companies, List -- SHANGHAI, Aug. 26 /PRNewswire-Asia-FirstCall/ -- ... ... ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Hikma - Half Year Results Interviews With CEO and CFO -- LONDON, August 26, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... bag of potato chips or pop in a DVD, you,re probably ... soap. Sputter deposition is an industrial process used since the ... various backings, like the metallic coating on potato chip bags, the ... Mostly, the process works very well. In a vacuum chamber filled ...
Cached Biology Technology:China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 2China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 3China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 4China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 5China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 6China-Biotics Ranked Number 62 on FORTUNE'S 100 Fastest-Growing Companies' List 7Hikma - Half Year Results Interviews With CEO and CFO 2Hikma - Half Year Results Interviews With CEO and CFO 3Hikma - Half Year Results Interviews With CEO and CFO 4Hikma - Half Year Results Interviews With CEO and CFO 5Trouble with sputter? Blame giant nanoparticles 2Trouble with sputter? Blame giant nanoparticles 3
(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... USC have found that a class of pharmaceuticals can ... , The drugs, known as "TSPO ligands," are currently ... at the effects of TSPO ligand in young adult ... in aged mice when pathology was quite severe," said ... of Gerontology. "TSPO ligand reduced measures of pathology and ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... This release is available in French ... Scientists from the Universit de Montral and its affiliated ... the National Sciences and Engineering Research Council of Canada ... institutions to launch training and mentorship programs for promising ...
... Almost two million years ago, early humans began eating food ... could have played an important role in the evolution of ... new research. In what is the first evidence of ... international team of researchers has discovered early stone tools and ...
... the atomic and molecular levels nanoscale have ... level where everything happens. Alexandra Navrotsky, Distinguished ... of its Nanomaterials in the Environment, Agriculture, and Technology ... throughout her career. She presented her findings today in ...
Cached Biology News:NSERC awards $3 million for UdeM and Polytechnique training programs 2Nanoparticle scientist speaks on new discoveries at Goldschmidt Conference 2